Eli Lilly Aktie

829,92USD 16,30USD 2,00%
Eli Lilly für 0 Euro bei ZERO ordern (zzgl. Spreads)
WKN: 858560 / ISIN: US5324571083
<
News + Analysen
News + Adhoc
Analysen
Kursziele
>
<
Unternehmen
Termine
Profil
>
<
zugeh. Wertpapiere
Zertifikate
Optionsscheine
Knock-Outs
>

Aktionärsstruktur

Inhaber in %
Freefloat 89,61
Lilly Endowment, Inc. 10,21
Lilly Endowment, Inc. 10,21
The Vanguard Group, Inc. 7,54
Vanguard Group, Inc. (Subfiler) 7,39
PNC Financial Services Group, Inc. (13F Subfiler) 5,41
PNC Bank, NA (Investment Management) 5,39
State Street Corp. 3,57
Vanguard Total Stock Market ETF 2,84
Fidelity Management & Research Co. LLC 2,53
BlackRock Fund Advisors 2,46
Vanguard 500 Index Fund 2,20
Capital Research & Management Co. (World Investors) 2,14
T Rowe Price Associates, Inc. (13F Subfiler) 2,09
BlackRock Institutional Trust Co. NA 1,87

*Die Summe der Anteile kann 100% überschreiten, da bestimmte Anteilseigner zum Freefloat dazu gerechnet wurden.

Personal

2019 2020 2021 2022 2023
Personal am Ende des Jahres 33 625 35 000 35 000 39 000 43 000
Umsatz pro Mitarbeiter in Mio. EUR 0,66 0,70 0,81 0,73 0,79

Bilanz (in Mio. USD) - Aktiva

2019 2020 2021 2022 2023
Summe Umlaufvermögen 13 710 17 462 18 452 18 035 25 727
Summe Anlagevermögen 25 577 29 171 30 354 31 455 38 279
Summe Aktiva 39 286 46 633 48 806 49 490 64 006

Bilanz (in Mio. USD) - Passiva

2019 2020 2021 2022 2023
Summe Fremdkapital 36 587 40 808 39 651 38 714 53 143
Summe Eigenkapital 2 699 5 825 9 155 10 775 10 864
Summe Passiva 39 286 46 633 48 806 49 490 64 006

Adresse

Lilly Corporate Center, 46285 Indianapolis
Telefon +1 (317) 276-2000
Internet http://www.lilly.com

Management

Alonzo Weems
Executive VP, Chief Ethics & Compliance Officer
Anat Hakim
Secretary, Executive VP & General Counsel
Andy Vicari
Senior Director & US Brand Leader-Insulins
Anne E. White
Executive Vice President-Lilly Neuroscience
Christian Nguyen
VP-Global Patient Outcomes & Real World Evidence
Daniel M. Skovronsky
Chief Scientific Officer & Executive VP
David A. Ricks
Chairman, President & Chief Executive Officer
David Hyman
Chief Medical Officer
Diogo Rau
Executive VP, Chief Information & Digital Officer
Donald A. Zakrowski
Chief Accounting Officer & Vice President-Finance
Edgardo Hernandez
President-Manufacturing Operations & Senior VP
Eric Dozier
Executive VP-Human Resources & Diversity
Gabrielle G. Greene-Sulzberger
Independent Director
Ilya Yuffa
Senior VP & President-Lilly Bio Medicines
Jacob S. van Naarden
Executive Vice President
Jamere Jackson
Independent Director
Jennifer Oleksiw
Global Chief Customer Officer & Vice President
Joe Fletcher
Investor Relations Contact
Jon Erik Fyrwald
Independent Director
Jon R. Moeller
Director
Juan Ricardo Luciano
Lead Independent Director
Katherine Baicker
Independent Director
Kim Macko
Head-Global Brand Development
Kimberly H. Johnson
Independent Director
Laura A. Lane
Vice President
Lucas E. Montarce
Chief Financial Officer & Executive Vice President
Mark Genovese
Senior Vice President-Immunology Development
Mary Lynne Hedley
Independent Director
Melissa Seymour
Executive Vice President-Global Quality
Nathaniel R. Miles
Vice President-Strategic Initiatives
Patrik Jonsson
EVP, President-Lilly Diabetes & Obesity
Ralph Alvarez
Independent Director
Robert Conley
Development Leader-Neuroscience
Robert J. Heine
Vice President-Medical Affairs
Ruth Gimeno
Vice President
Thomas Fuchs
Chief Artificial Intelligence Officer
Travis Coy
VP, Head-Transactions & Business Development
William G. Kaelin
Independent Director